BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/16/2021 7:46:10 AM | Browse: 301 | Download: 719
 |
Received |
|
2021-02-03 06:27 |
|
Peer-Review Started |
|
2021-02-03 06:32 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-08-19 19:20 |
|
Revised |
|
2021-09-01 04:04 |
|
Second Decision |
|
2021-12-07 03:16 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2021-12-08 06:08 |
|
Articles in Press |
|
2021-12-08 06:08 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2021-11-23 07:49 |
|
Typeset the Manuscript |
|
2021-12-13 06:43 |
|
Publish the Manuscript Online |
|
2021-12-16 07:46 |
| ISSN |
1948-9358 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Endocrinology & Metabolism |
| Manuscript Type |
Retrospective Study |
| Article Title |
Efficacy of omarigliptin, once-weekly dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Eiji Kawasaki, Yuko Nakano, Takahiro Fukuyama, Aira Uchida, Yoko Sagara, Hidekazu Tamai, Masayuki Tojikubo, Yuji Hiromatsu and Nobuhiko Koga |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Eiji Kawasaki, MD, PhD, Director, Department of Diabetes and Endocrinology, Shin-Koga Hospital, 120 Tenjin-cho, Kurume 830-8577, Japan. e-kawasaki@tenjinkai.or.jp |
| Key Words |
Omarigliptin; Once-weekly dipeptidyl peptidase-4 inhibitor; Real-world practice; Retrospective study; Type 2 diabetes |
| Core Tip |
This paper reported on the efficacy of omarigliptin in Japanese patients with type 2 diabetes who had previously received treatment with other glucose-lowering agents. The present study demonstrated that administering omarigliptin as add-on therapy or switching to it from sitagliptin and linagliptin, but not vildagliptin, provides more effective glycemic control. Ultimately, these findings should help decision-making in the actual clinical setting when selecting and using dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes. |
| Publish Date |
2021-12-16 07:46 |
| Citation |
Kawasaki E, Nakano Y, Fukuyama T, Uchida A, Sagara Y, Tamai H, Tojikubo M, Hiromatsu Y, Koga N. Efficacy of omarigliptin, once-weekly dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes. World J Diabetes 2021; 12(12): 2087-2095 |
| URL |
https://www.wjgnet.com/1948-9358/full/v12/i12/2087.htm |
| DOI |
https://dx.doi.org/10.4239/wjd.v12.i12.2087 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
